Abstract:// Jing Guo 1 , Yage Yang 1, 2 , Yunsheng Yang 1 , Enqiang Linghu 1 , Qimin Zhan 3 , Malcolm V. Brock 4 , James G. Herman 4 , Bingyong Zhang 5 , Mingzhou Guo 1 1 Department of Gastroenterology & Hepatology, Chinese PLA General Hospital, Beijing 100853, P.R.China 2 Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R.China 3 State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, P.R.China 4 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, U.S.A 5 Department of Gastroenterology and Hepatology, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, P.R.China Correspondence to: Mingzhou Guo, e-mail: mzguo1@gmail.com Bingyong Zhang, e-mail: zhbingyong@sina.com.cn James G. Herman, e-mail: hermaji@jhmi.edu Keywords: RASSF10, DNA methylation, P53 signaling, colorectal cancer, epigenetics Received: August 24, 2014 Accepted: December 07, 2014 Published: December 27, 2014 ABSTRACT RASSF10 has previously been reported to be frequently methylated in a number of malignancies. To understand the importance of RASSF10 inactivation in colorectal carcinogenesis, eight colorectal cancer cell lines, 89 cases of primary colorectal cancer and 5 cases of normal colorectal mucosa were examined. Methylation specific PCR, western blot, siRNA, gene expression array and xenograft mice were employed. The expression of RASSF10 was regulated by promoter regional methylation in colorectal cancer cells. RASSF10 was methylated in 60.7% (54/89) of primary colorectal cancers and was positively associated with tumor stage ( p < 0.05) and metastasis ( p < 0.05). Restoration of RASSF10 led to inhibition of colorectal cancer cell proliferation in vitro and in vivo and increased apoptosis. Gene expression arrays discovered RASSF10 inhibition of MDM2 expression as a mediator of these effects, which was confirmed with RT- PCR and western blot. RASSF10 was shown to activate P53 signaling in RKO and HCT116 cells after UV exposure, and sensitized these cells to docetaxel. In conclusion, our study demonstrates RASSF10 is frequently methylated in human colorectal cancer leading to loss of expression. RASSF10 normally suppresses human colorectal cancer growth by activating P53 signaling in colorectal cancer, and restored expression sensitizes colorectal cancer to docetaxel.

Paired Box Gene 5 is A Novel Tumor Suppressor Involved in the Pathogenesis of Hepatocellular Carcinoma Through Interaction with P53 Signaling Pathway

Ras-association Domain Family 10 Acts As a Novel Tumor Suppressor Through Modulating MMP2 in Hepatocarcinoma

RASSF10 Suppresses Hepatocellular Carcinoma Growth by Activating P53 Signaling and Methylation of RASSF10 is a Docetaxel Resistant Marker

SRSF10 Facilitates HCC Growth and Metastasis by Suppressing CD8+T Cell Infiltration and Targeting SRSF10 Enhances Anti-Pd-l1 Therapy

Abstract 2988: Loss of Rbm38 Cooperates with Mutant P53 to Promote Lymphomagenesis Through Downregulation of Pten

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Rassf10 Suppresses Colorectal Cancer Growth By Activating P53 Signaling And Sensitizes Colorectal Cancer Cell To Docetaxel

RASSF10 is an Epigenetically Inactivated Tumor Suppressor and Independent Prognostic Factor in Hepatocellular Carcinoma

22 Epigenetic Identification of Paired Box Gene 5 As a Functional Tumor Suppressor Associated with Poor Prognosis in Patients with Gastric Cancer

Homeobox D10 Gene, a Candidate Tumor Suppressor, is Downregulated Through Promoter Hypermethylation and Associated with Gastric Carcinogenesis

Rpn10 promotes tumor progression by regulating hypoxia-inducible factor 1 alpha through the PTEN/Akt signaling pathway in hepatocellular carcinoma.

Tumor Suppressor RASSF1A Promoter: P53 Binding and Methylation

Novel Evidence for Retinoic Acid-Induced G (Rig-G) As a Tumor Suppressor by Activating P53 Signaling Pathway in Lung Cancer.

RASSF1A Expression Inhibits the Growth of Hepatocellular Carcinoma from Qidong County.

Novel Tumor Suppressive Role of the RAS GTPase-Activating Protein RASA5 to RAS Signaling Perturbation in Human Carcinomas

Paired Box 5 is a Frequently Methylated Lung Cancer Tumour Suppressor Gene Interfering Β‐catenin Signalling and GADD45G Expression

Tumor Suppression of Ras GTPase-Activating Protein RASA5 Through Antagonizing Ras Signaling Perturbation in Carcinomas.

RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma

Epigenetic Silencing of RASSF10 Promotes Tumor Growth in Esophageal Squamous Cell Carcinoma.

RASSF10 Exhibits Tumor‑suppressing Potential Involving Tumor Proliferation, Metastasis and Epithelial‑mesenchymal Transition in Esophageal Squamous Cell Carcinoma.